BactiQuant (BACTIQ) Q3 2025 TU earnings summary

Executive summary

• Revenue for Q3 2025 increased by 24% year-over-year, with strong contributions from Pharma and Aquaculture segments.

• Pharma saw significant growth in recurring consumables, while Aquaculture rebounded with 75% growth in Q3 compared to last year.

• Management expects continued and accelerated growth, supported by a solid sales pipeline.

Financial highlights

• Total revenue for the first nine months of 2025 reached DKK 5.5 million, up 24% from the same period in 2024.

• Largest segment was Pharma, accounting for 33% of revenue.

• Recurring revenue grew moderately by 8% year-over-year, while hardware sales increased by 28%.

• Other category (accessories, service, freight) grew by 114% year-over-year.

Outlook and guidance

• Full-year 2025 revenue is expected in the range of DKK 8–11 million.

• EBITDA for 2025 is forecasted between DKK -9 million and DKK -12 million, unchanged from previous guidance.